Assessment of Molecular Response to Gilteritinib in FLT3 Mutation–Positive Relapsed/Refractory Acute Myeloid Leukemia

Conference Correspondent - ASCO 2017 - Acute Myeloid Leukemia

In prior studies, gilteritinib, a selective FLT3/AXL inhibitor, displayed clinical activity in FLT3 mutation–positive relapsed/refractory acute myeloid leukemia (AML). In this analysis, researchers assessed molecular response to gilteritinib in a clinical trial subpopulation.

Molecular response was assessed in adult patients with FLT3 mutation–positive AML treated with gilteritinib 120 or 200 mg daily. Response was evaluated at baseline and at least 1 subsequent time point. A Cox regression model of overall survival (OS) by Kaplan-Meier estimation was utilized to determine an internal tandem duplication (ITD) signal ratio indicative of improved survival.

A total of 80 patients with FLT3 mutation–positive AML who received gilteritinib 120 or 200 mg daily were included in the analysis. Median age was 61 years; 22 (28%) patients had prior FLT3 tyrosine kinase inhibitor therapy. A total of 20 (25%) patients showed a molecular response to treatment. Of these 20 patients, 18 had a ratio of ≤10−3, indicative of major molecular response, and 13 had a ratio of ≤10−4, indicative of minimal residual disease–negative status. These patients had significantly longer median OS than those who did not.

In this first demonstration of molecular response to an FLT3 inhibitor in relapsed/refractory AML, molecular responses to gilteritinib correlated with clinical response and improved OS. Although further investigation is warranted, the preliminary data suggest that the ITD signal ratio may predict the durable clinical benefit of gilteritinib.

Altman JK, et al. ASCO Abstract 7003.

Related Items
Suboptimal Adherence to Guideline-Recommended Molecular Testing in Patients with Newly Diagnosed AML: Data from the Connect MDS/AML Disease Registry
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia, Conference Correspondent
Effect of Cytarabine/Anthracycline/Crenolanib Induction on MRD in Newly Diagnosed FLT3 Mutant AML
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Differentiation Syndrome Associated with Enasidenib, a Selective Inhibitor of mIDH2
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Outcomes with Lower-Intensity Therapy in TP53-Mutated AML
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Enasidenib in Mutant-IDH2 Relapsed or Refractory AML: Results of a Phase 1 Dose-Escalation and Expansion Study
Conference Correspondent published on June 5, 2017 in ASCO 2017 - Acute Myeloid Leukemia
Last modified: June 8, 2017
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME